OcuLenz headset showcased at CES 2024 and available for pre-order as visual aid for AMD


The commercial release of OcuLenz is planned for the first half of 2024. Ocutrx is collaborating with Medicare and insurance providers to ensure the headset's affordability and accessibility.

Person holding VR headset (Image credit: AdobeStock/insta_photos)

(Image credit: AdobeStock/insta_photos)

At the ShowStoppers event during CES 2024, Ocutrx Technologies, Inc. presented a demonstration of the OcuLenz™, their innovative AR/XR headset with the widest field-of-view and the highest resolution in all of AR. Ocutrx's OcuLenz, an innovative AR/XR headset, is engineered to address advanced macular degeneration (AMD), to combine functionality and comfort, will advancing visual aid technology.

Using advanced pixel manipulation, it overlays high-contrast images onto the user's field of view, compensating for AMD's central vision loss by shifting images to the peripheral vision. Powered by the Qualcomm Snapdragon® XR2 processor, OcuLenz offers a high-resolution (2.5K per eye) experience with a 72-degree wide field-of-view. Designed to be lightweight and easy to use, OcuLenz enhances visual perception and interaction with the environment, significantly aiding those affected by AMD. It also has a patented interpupillary distance adjustment to prevent dizziness.

Expanding Applications Beyond AMD

With its Software Development Kit (SDK), OcuLenz use now extends to areas like enterprise, military, medical assistance, and more. The ORLenz™ is Ocutrx's patented AR/XR headset platform for surgeons, and the DigiLoupe™ is the AR/XR stand-alone digital loupe for dentists, dermatologists, and non-microscope surgeries for spine, orthopedic, and neurosurgeons.

Michael Freeman, CEO of Ocutrx, shares his personal connection to the device’s use, saying, "OcuLenz for patients and its related surgery devices, the ORLenz and the DigiLoupe isn't just a product; it's a key platform to serve many verticals and a more enriched life for many. With 18 AR/XR wearable patents, it represents a substantial AR/XR technology leap, moving well beyond its initial focus on AMD. Inspired by my father's journey, we've created a solution that enhances vision and offers hope and possibilities to individuals facing vision-similar challenges and can be used in many non-medical applications."

Gaining Worldwide Attention

OcuLenz, Ocutrx's AR/XR headset, has captured global attention, demonstrating its wide-ranging applicability and potential for international adoption. The 42 Ocutrx Medical Advisors hail from the US, Mexico, South America, Europe, the United Kingdom, and Asia, Garnering interest from major healthcare distributors in regions such as the Middle East and Europe, including countries like Saudi Arabia, Dubai, the Netherlands, Spain, and Italy, the headset's versatility and appeal has been noted across diverse international markets.

Pre-Order Launch

In response to this growing global demand, Ocutrx is now available for individual patients and bulk orders, catering to low vision centers, optometrists, and ophthalmologists to pre-order. This broad availability signifies Ocutrx's commitment to meeting the diverse needs of both individual patients and professional healthcare providers.

The commercial release of OcuLenz is planned for the first half of 2024. Ocutrx is collaborating with Medicare and insurance providers to ensure the headset's affordability and accessibility. More detailed information about the product design, technological insights, and its impact on AMD and Stargardt's disease can be found at OculenzAMD.com.

1. OCUTRX Debuts Latest AR/XR Vision Headset at CES 2024: Revealing Expanded Uses, Surging Global Interest, and New Pre-Order Opportunities. Ocutrx technologies, Inc. Published January 9, 2024. Accessed January 15, 2024. https://www.prnewswire.com/news-releases/ocutrx-debuts-latest-arxr-vision-headset-at-ces-2024-revealing-expanded-uses-surging-global-interest-and-new-pre-order-opportunities-302029805.html
© 2024 MJH Life Sciences

All rights reserved.